CHYM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CHYM is a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. My view is a clear BUY because the stock has supportive analyst momentum, improving fundamentals, and a favorable options sentiment backdrop, while the technical setup is constructive but not overheated. Since the user is impatient and does not want to wait for the ideal entry, this is still a reasonable entry now rather than a stock to keep watching. The only meaningful near-term caution is earnings next week, but the overall setup still favors buying over waiting.
CHYM is in a mild uptrend but not in a breakout state. Price closed at 22.035, slightly above support at S1 21.339 and below pivot resistance at 22.809, which puts it near the middle of a short-term range. RSI_6 at 44.9 is neutral, suggesting room to move higher without being overbought. MACD histogram is negative and expanding, so momentum is not fully confirmed yet. Moving averages are converging, which usually signals a potential trend inflection. Near-term downside appears limited around 21.34 and 20.43, while upside levels are 24.28 and 25.19. The stock trend model also implies positive near-term drift over 1 week and 1 month.
["BMO Capital initiated coverage with an Outperform rating and $30 price target, calling Chime\u2019s monetization opportunity underappreciated.", "Texas Capital initiated Buy with a $28 target and expects continued consumer growth through 2028.", "Wells Fargo initiated Overweight and highlighted attractive growth plus profitability.", "KeyBanc sees a long runway for share gains and strong model profitability.", "Financials show strong Q4 revenue growth of 25.49% year over year and gross margin expansion to 88.2%.", "Upcoming QMAR 2026 earnings on 2026-05-06 could serve as a catalyst if results beat the very low EPS estimate of 0.03.", "Options positioning is bullish with a low put-call open interest ratio of 0.35."]
["MACD histogram is negative and widening, indicating momentum is not yet fully confirmed.", "The stock is still below the pivot resistance at 22.809, so it has not clearly broken out yet.", "Q4 net income and EPS are still negative, even though both improved year over year.", "Analyst targets have shown some spread, with UBS remaining Neutral and Compass Point cutting its target from 33 to 27.", "Earnings are coming soon, which can create a near-term binary reaction."]
Latest reported quarter: Q4 2025. Revenue rose to $596.4M, up 25.49% year over year, showing strong top-line growth. Gross margin improved to 88.2%, which is very strong and slightly higher than last year. Net income remained negative at -$44.8M, but the loss narrowed sharply year over year. EPS was -0.12, also improving meaningfully versus the prior year. Overall, the latest quarter shows strong growth and improving profitability trends, which supports a long-term bullish thesis.
Analyst sentiment is positive and improving. Recent initiations from BMO, Texas Capital, Wells Fargo, and KeyBanc were all bullish, with price targets mostly in the $28-$30 range. Earlier in the year, Evercore remained Outperform and UBS stayed Neutral, while Compass Point upgraded to Buy but trimmed its target. Morgan Stanley kept Overweight but reduced its target on peer multiple compression. Overall Wall Street pros view CHYM favorably for growth, monetization, and profitability upside, with a few cautious voices still present. There is no recent notable politician or congressional trading activity reported for this stock.
